For the seventh year, the world’s leading societies in the field of thoracic oncology are collaborating to host the European Lung Cancer Conference (ELCC), a multidisciplinary event that aims to advance science, disseminate education, and improve lung cancer care worldwide. The conference, to be held May 5–8 in Geneva, Switzerland, will be hosted by IASLC and the European Society for Medical Oncology (ESMO), in partnership with the European Society for Radiotherapy and Oncology, European Society of Thoracic Surgeons, and European Thoracic Oncology Platform.
“I am excited to be involved in this partnership between IASLC and ESMO. It brings together the best healthcare specialists from around the world in order to present, discuss, and advance our understanding of thoracic malignancies,” said IASLC’s co-chair of the conference’s Scientific Committee, Andrew Nicholson, Head of Diagnostic Thoracic Pathology at the Royal Brompton Hospital and Honorary Professor of Respiratory Pathology, National Heart and Lung Institute, Imperial College London. He shares leadership of the committee with ESMO’s Martin Reck, Head of the Department of Thoracic Oncology and the Clinical Trial Department in the Department of Thoracic Oncology at the Lung Clinic Grosshansdorf in Germany. ELCC 2017 will convene medical oncologists, radiation oncologists, thoracic surgeons, respiratory physicians/ pulmonologists, interventional radiologists, pathologists, and other medical professionals involved in the diagnosis, treatment, and follow-up of patients with lung cancer. Attendees will discuss multidisciplinary clinical practice, receive updates on how molecular biology and immunology are changing the tumor treatment landscape, and learn the latest advances in translational and clinical research in lung and other thoracic malignancies.
Keynote lectures will focus on “Genetic Profiling of Lung Cancer,” “Molecular Clonal Development of Lung Cancer,” and “The Implementation of Screening.”
Other sessions will address:
• Staging and classification of lung cancer, including the new IASLC staging system
• ESMO recommendations for thoracic malignancies
• Immunotherapy: first-line treatment, biomarkers, and combination approaches
• Management of brain metastases
• Diagnosis and management of molecularly defined non-small cell lung cancer
• Small cell lung cancer and mesothelioma
• Rare thoracic malignancies
• Thymic tumors
• Management of dyspnea and cachexia
• Lung cancer presenting through the emergency room
• The role of the pathologist in guiding therapy
• Smoking prevention and cessation
• Screening and early detection
• Topics in chemotherapy and radiotherapy
In addition, the conference will feature poster presentations, best abstracts from ESMO-IASLC, and satellite symposia and exhibits supported by industry.
The educational programming has been submitted for accreditation through the Medical Oncologist’s Recertification Approval program for medical oncologists to remain certified by ESMO as well as the European Accreditation Council for Continuing Medical Education (EACCME) for continuing medical education credits for medical specialists. Physicians may convert EACCME credits to an equivalent number of credits through the American Medical Association.
For more information and to register, visit ESMO.org/Conferences/ELCC- 2017-Lung-Cancer or contact the IASLC at email@example.com. After the conference, webcasts of sessions will be available to IASLC and ESMO members.✦